607 related articles for article (PubMed ID: 16828740)
1. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Biochem Biophys Res Commun; 2006 Jun; 344(2):688-95. PubMed ID: 16631124
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
4. Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
Izumi T; Iwamoto N; Kitaichi Y; Kato A; Inoue T; Koyama T
Eur J Pharmacol; 2007 Jun; 565(1-3):105-12. PubMed ID: 17400208
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Fisar Z; Hroudová J; Raboch J
Neuro Endocrinol Lett; 2010; 31(5):645-56. PubMed ID: 21200377
[TBL] [Abstract][Full Text] [Related]
6. Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish.
Sallinen V; Sundvik M; Reenilä I; Peitsaro N; Khrustalyov D; Anichtchik O; Toleikyte G; Kaslin J; Panula P
J Neurochem; 2009 Apr; 109(2):403-15. PubMed ID: 19222706
[TBL] [Abstract][Full Text] [Related]
7. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
Kitaichi Y; Inoue T; Nakagawa S; Boku S; Izumi T; Koyama T
Eur J Pharmacol; 2010 Jul; 637(1-3):77-82. PubMed ID: 20406628
[TBL] [Abstract][Full Text] [Related]
9. The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.
Bour S; Iglesias-Osma MC; Marti L; Duro P; Garcia-Barrado MJ; Pastor MF; Prévot D; Visentin V; Valet P; Moratinos J; Carpéné C
Eur J Pharmacol; 2006 Dec; 552(1-3):20-30. PubMed ID: 17056035
[TBL] [Abstract][Full Text] [Related]
10. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
11. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits.
Sprague JE; Nichols DE
J Pharmacol Exp Ther; 1995 May; 273(2):667-73. PubMed ID: 7538579
[TBL] [Abstract][Full Text] [Related]
12. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
13. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Santana L; González-Díaz H; Quezada E; Uriarte E; Yáñez M; Viña D; Orallo F
J Med Chem; 2008 Nov; 51(21):6740-51. PubMed ID: 18834112
[TBL] [Abstract][Full Text] [Related]
15. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
Tekes K; Magyar K
Neurobiology (Bp); 2000; 8(3-4):257-64. PubMed ID: 11225517
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.
Guang HM; Du GH
Acta Pharmacol Sin; 2006 Jun; 27(6):760-6. PubMed ID: 16723097
[TBL] [Abstract][Full Text] [Related]
17. The properties of B-form monoamine oxidase in mitochondria from monkey platelet.
Obata T; Aomine M
Res Commun Mol Pathol Pharmacol; 2009-2010; 122-123(1-6):13-26. PubMed ID: 22032088
[TBL] [Abstract][Full Text] [Related]
18. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
Fagervall I; Ross SB
J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
20. "In vitro" effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system.
Morón JA; Perez V; Fernández-Alvarez E; Marco JL; Unzeta M
J Neural Transm Suppl; 1998; 52():343-9. PubMed ID: 9564637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
